These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Reducing prostate biopsies and magnetic resonance imaging with prostate cancer risk stratification. Davik P; Remmers S; Elschot M; Roobol MJ; Bathen TF; Bertilsson H BJUI Compass; 2022 Sep; 3(5):344-353. PubMed ID: 35950035 [TBL] [Abstract][Full Text] [Related]
3. Does Multiparametric Magnetic Resonance of Prostate Outperform Risk Calculators in Predicting Prostate Cancer in Biopsy Naïve Patients? Falagario UG; Silecchia G; Bruno SM; Di Nauta M; Auciello M; Sanguedolce F; Milillo P; Macarini L; Selvaggio O; Carrieri G; Cormio L Front Oncol; 2020; 10():603384. PubMed ID: 33489907 [TBL] [Abstract][Full Text] [Related]
4. Incorporating PHI in decision making: external validation of the Rotterdam risk calculators for detection of prostate cancer. Rius Bilbao L; Aguirre Larracoechea U; Valladares Gomez C; Remmers S; Mar Medina C; World J Urol; 2024 Mar; 42(1):141. PubMed ID: 38478041 [TBL] [Abstract][Full Text] [Related]
5. Head-to-head Comparison of Conventional, and Image- and Biomarker-based Prostate Cancer Risk Calculators. Mortezavi A; Palsdottir T; Eklund M; Chellappa V; Murugan SK; Saba K; Ankerst DP; Haug ES; Nordström T Eur Urol Focus; 2021 May; 7(3):546-553. PubMed ID: 32451315 [TBL] [Abstract][Full Text] [Related]
6. External Validation of the Prostate Biopsy Collaborative Group Risk Calculator and the Rotterdam Prostate Cancer Risk Calculator in a Swedish Population-based Screening Cohort. Chandra Engel J; Palsdottir T; Ankerst D; Remmers S; Mortezavi A; Chellappa V; Egevad L; Grönberg H; Eklund M; Nordström T Eur Urol Open Sci; 2022 Jul; 41():1-7. PubMed ID: 35813248 [TBL] [Abstract][Full Text] [Related]
7. External validation of two mpMRI-risk calculators predicting risk of prostate cancer before biopsy. Pallauf M; Steinkohl F; Zimmermann G; Horetzky M; Rajwa P; Pradere B; Lindner AK; Pichler R; Kunit T; Shariat SF; Lusuardi L; Drerup M World J Urol; 2022 Oct; 40(10):2451-2457. PubMed ID: 35941246 [TBL] [Abstract][Full Text] [Related]
8. Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators. Alberts AR; Roobol MJ; Verbeek JFM; Schoots IG; Chiu PK; Osses DF; Tijsterman JD; Beerlage HP; Mannaerts CK; Schimmöller L; Albers P; Arsov C Eur Urol; 2019 Feb; 75(2):310-318. PubMed ID: 30082150 [TBL] [Abstract][Full Text] [Related]
9. Observational study comparing the accuracy/variability between the ERSPC and the PCPT risk calculators for the prediction of significant prostate cancer in patients with PSA <10 ng/mL. Gomez Gomez E; Salamanca Bustos JJ; Carrasco Valiente J; Fernandez Rueda JL; Blanca A; Valero Rosa J; Bravo Arrebola I; Marquez López J; Jimenez Vacas JM; Luque R; Requena Tapia MJ BMJ Open; 2019 Nov; 9(11):e031032. PubMed ID: 31722940 [TBL] [Abstract][Full Text] [Related]
10. Prostate cancer risk prediction using the novel versions of the European Randomised Study for Screening of Prostate Cancer (ERSPC) and Prostate Cancer Prevention Trial (PCPT) risk calculators: independent validation and comparison in a contemporary European cohort. Poyet C; Nieboer D; Bhindi B; Kulkarni GS; Wiederkehr C; Wettstein MS; Largo R; Wild P; Sulser T; Hermanns T BJU Int; 2016 Mar; 117(3):401-8. PubMed ID: 26332503 [TBL] [Abstract][Full Text] [Related]
11. Comparison of risk calculators from the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer in a contemporary Canadian cohort. Trottier G; Roobol MJ; Lawrentschuk N; Boström PJ; Fernandes KA; Finelli A; Chadwick K; Evans A; van der Kwast TH; Toi A; Zlotta AR; Fleshner NE BJU Int; 2011 Oct; 108(8 Pt 2):E237-44. PubMed ID: 21507190 [TBL] [Abstract][Full Text] [Related]
12. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3? Zhang Y; Zeng N; Zhang F; Huang Y; Tian Y Int J Clin Oncol; 2020 Jan; 25(1):175-186. PubMed ID: 31473884 [TBL] [Abstract][Full Text] [Related]
13. Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators. Roobol MJ; van Vugt HA; Loeb S; Zhu X; Bul M; Bangma CH; van Leenders AG; Steyerberg EW; Schröder FH Eur Urol; 2012 Mar; 61(3):577-83. PubMed ID: 22104592 [TBL] [Abstract][Full Text] [Related]
14. The Mount Sinai Prebiopsy Risk Calculator for Predicting any Prostate Cancer and Clinically Significant Prostate Cancer: Development of a Risk Predictive Tool and Validation with Advanced Neural Networking, Prostate Magnetic Resonance Imaging Outcome Database, and European Randomized Study of Screening for Prostate Cancer Risk Calculator. Parekh S; Ratnani P; Falagario U; Lundon D; Kewlani D; Nasri J; Dovey Z; Stroumbakis D; Ranti D; Grauer R; Sobotka S; Pedraza A; Wagaskar V; Mistry L; Jambor I; Lantz A; Ettala O; Stabile A; Taimen P; Aronen HJ; Knaapila J; Perez IM; Gandaglia G; Martini A; Picker W; Haug E; Cormio L; Nordström T; Briganti A; Boström PJ; Carrieri G; Haines K; Gorin MA; Wiklund P; Menon M; Tewari A Eur Urol Open Sci; 2022 Jul; 41():45-54. PubMed ID: 35813258 [TBL] [Abstract][Full Text] [Related]
15. European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators significantly outperform the Prostate Cancer Prevention Trial (PCPT) 2.0 in the prediction of prostate cancer: a multi-institutional study. Foley RW; Maweni RM; Gorman L; Murphy K; Lundon DJ; Durkan G; Power R; O'Brien F; O'Malley KJ; Galvin DJ; Brendan Murphy T; William Watson R BJU Int; 2016 Nov; 118(5):706-713. PubMed ID: 26833820 [TBL] [Abstract][Full Text] [Related]
16. Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis. Louie KS; Seigneurin A; Cathcart P; Sasieni P Ann Oncol; 2015 May; 26(5):848-864. PubMed ID: 25403590 [TBL] [Abstract][Full Text] [Related]
17. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies. Radtke JP; Wiesenfarth M; Kesch C; Freitag MT; Alt CD; Celik K; Distler F; Roth W; Wieczorek K; Stock C; Duensing S; Roethke MC; Teber D; Schlemmer HP; Hohenfellner M; Bonekamp D; Hadaschik BA Eur Urol; 2017 Dec; 72(6):888-896. PubMed ID: 28400169 [TBL] [Abstract][Full Text] [Related]
18. Performance of magnetic resonance imaging-based prostate cancer risk calculators and decision strategies in two large European medical centres. Davik P; Remmers S; Elschot M; Roobol MJ; Bathen TF; Bertilsson H BJU Int; 2024 Mar; 133(3):278-288. PubMed ID: 37607322 [TBL] [Abstract][Full Text] [Related]
19. Prediction of Prostate Cancer: External Validation of the ERSPC Risk Calculator in a Contemporary Dutch Clinical Cohort. Gayet M; Mannaerts CK; Nieboer D; Beerlage HP; Wijkstra H; Mulders PFA; Roobol MJ Eur Urol Focus; 2018 Mar; 4(2):228-234. PubMed ID: 28753781 [TBL] [Abstract][Full Text] [Related]
20. Comparison of Magnetic Resonance Imaging-Based Risk Calculators to Predict Prostate Cancer Risk. Patel HD; Remmers S; Ellis JL; Li EV; Roobol MJ; Fang AM; Davik P; Rais-Bahrami S; Murphy AB; Ross AE; Gupta GN JAMA Netw Open; 2024 Mar; 7(3):e241516. PubMed ID: 38451522 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]